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Objectives. This study sought o evaluate the efficacy and safety 
of arbutamine when used in conjunction with thallium-201 single- 
photon emission computed tomography (SPECT) in a multicenter 
trial and to compare arbutamine stress and treadmill exercise 
thallium-201 SPECT for diagnostic sensitivity and myocardial 
perfusion pattern. 
Background. Arbutamine is a potent beta-agonist developed 
specifically for pharmacologic stress testing. 
Methods. Arbutamine was administered by a novel computer- 
ized closed-loop device that measures heart rate and adjusts 
arbutamine infusion to achieve a selected rate of heart rate 
increase toward a predetermined limit. The cohort included 184 
patients who underwent arbutamine stress testing, of whom 122 
(catheterization group) had angiographically defined coronary 
artery disease (>50% diameter stenosis of a major coronary 
artery), and 62 had a low pretest likelihood of coronary artery 
disease (low likelihood group). A subset of 69 patients from the 
catheterization group underwent both arbutamine and exercise 
stress testing. 
Results. Hemodynamic responses during arbutamine and exer- 
cise stress testing demonstrated nosignificant difference in per- 
cent increase in heart rate (81% vs. 76%) or systolic blood 
pressure (26% vs. 30%). The sensitivity for detecting coronary 
artery disease (>50% stenosis) using arbutamine thallium-201 
SPECT was 87% (95% for detecting >70% stenoses), and the 
normalcy rate in the low likelihood group was 90%. In patients 
completing both arbutamine and exercise stress testing, thallium- 
201 SPECT sensitivity for detecting coronary artery disease 
(>500 stenosis) was 94% and 97% (p = NS), respectively. 
Furthermore, SPECT segmental visual score agreement (defect 
vs. no defect) showed a concordance of92% between arbutamine 
and exercise results (kappa 0.80, p < 0.001). The stress thallium- 
201 SPECT segmental scores howed 83% exact agreement (kappa 
0.69, p < 0.001), and analysis of the reversibility of segments with 
stress perfusion defects demonstrated 86% exact agreement 
(kappa 0.68, p < 0.001). In general, side effects associated with 
arbutamine were well tolerated and resolved with discontinuation 
of infusion. 
Conclusions. Arbutamine, administered by a closed.loop feed- 
back system was shown to be a safe and effective pharmacologic 
stress agent. Arbutamine stress thallium-201 SPECT appears to 
be accurate for the diagnosis of coronary artery disease with a 
diagnostic efficacy similar to that of treadmill exercise thallium- 
201 studies. 
(J Am Coil Cardiol 1995;26:1159-67) 
Exercise myocardial perfusion imaging is a widely used and 
established diagnostic test for the evaluation of coronary artery 
disease (1), but its optimal diagnostic efficacy depends on 
achieving an adequate heart rate during exercise (2). However, 
a substantial number of patients referred to stress laboratories 
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cannot achieve adequate xercise heart rates for a variety of 
reasons, including debility; physical deconditioning; pulmo- 
nary, peripheral vascular or orthopedic diseases; and beta- 
adrenergic blocking agent herapy. With aging of the general 
population and an increased number of indications for myo- 
cardial stress evaluations, the proportion of patients referred 
for stress tests using pharmacologic approaches is expected to 
increase (3). 
Dipyridamole (4,5) and adenosine (6,7) are vasodilators 
that have been used as pharmacologic stress agents. With 
these agents, a scintigraphic myocardial perfusion abnor- 
mality is generally produced as a result of a heterogeneous 
hyperemic response within the myocardial coronary beds, 
with little increase in myocardial work load (defined by 
rate-pressure product). 
In contrast, the beta-receptor agonists (e.g., dobutamine, 
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Table 1. Baseline Demographic Characteristics of the Two 
Study Groups 
Catheterization Low Likelihood 
Group Group 
(n - 122) (n = 62) 
Age (yr [mean = SD]) 59 _+ 10 43 _+ 12 
Men/women (no.) 103/19 59/3 
Cardiac history, 
Myocardial infarction 60 (49%) 0 
Hypertension 60 (49%) 15 (24%) 
Chest pain 107 (88%) 28 (45%)* 
Cardiac medications 
Calcium channel blockers 89 (73%) 5 (8%) 
Nitrates 79 (65%) 0 
Beta-blockers 55 (45%) 0 
Coronary artery, disease 
One-vessel 36 (30%) NA 
Two-vessel 44 (36%) NA 
Three-vessel 41 (34%) NA 
*Nonspecific hest pain. Unless otherwise indicated, data presented are 
number (%) of patients. NA = not applicable, coronary, angiography not 
required. 
arbutamine) may induce myocardial ischemia by their positive 
inotropic and chronotropic as well as peripheral pressor effects 
(8-11), simulating the hemodynamic response to exercise. 
Preclinical findings suggest hat arbutamine may induce isch- 
emia more effectively than dobutamine because higher doses 
of dobutamine are required to elicit chronotropic activiW, 
whereas inotropic and chronotropic activity increase propor- 
tionately at similar arbutamine doses (1132). In the present 
multicenter t ial, arbutamine, a new synthetic atecholamine 
developed specifically for pharmacologic stress testing and 
approved for clinical use in several European countries, was 
evaluated. The objectives of the trial were to 1) determine the 
sensitivity and normalcy rate (estimate of specificity) of arbu- 
tamine stress used in conjunction with thallium-201 single- 
photon emission computed tomography (SPECT); 2) compare 
the sensitivity of exercise and arbutamine thallium-201 SPECT 
in patients undergoing both forms of stress studies; and 3) 
assess the clinical safety and tolerability of arbutamine and its 
dedicated infusion device. 
Methods 
Study patients. A total of 184 patients (Table 1) from two 
patient groups underwent arbutamine stress testing. The 122 
patients in the catheterization group were recruited for evalu- 
ation of the sensitivity of arbutamine thallium-201 SPECT for 
detecting coronary artery disease. All had angiographically 
proven coronary artery disease (->50% stenosis in one or more 
major coronary vessels). Arbutamine stress tests were per- 
formed within 14 weeks of coronary angiography (angiography 
was performed first in 107 patients, arbutamine stress first in 
15). If physically capable, patients in the catheterization group 
also performed an exercise treadmill thallium-201 study. In 
these 69 patients, the order of testing was randomly assigned, 
and the second test was performed within 5 to 14 days after the 
first test (treadmill first in 35 patients, arbutamine first in 34). 
An additional eight patients who had normal coronary 
angiographic findings were excluded by study design from the 
catheterization group. Of these eight patients, six had abnor- 
mal results on (as defined later) arbutamine scintigraphic 
testing most likely because of differences in the interpretation 
of the angiogram by central and local laboratories, prior 
history of myocardial infarction or the operation of posttest 
referral biases (13,14). No serious adverse vents occurred in 
these eight patients. 
The 62 patients in the low likelihood group were recruited 
for evaluation of the normalcy rate of arbutamine thallium-201 
SPECT studies. All patients had been clinically referred for 
cardiac workup. Before arbutamine t sting, patients had a low 
(<5%) likelihood of coronary artery disease defined by se- 
quential Bayesian analysis (15) and a ->98% probability of 
5-year survival defined by the Duke exercise treadmill score 
(16). 
Patients with acute myocardial infarction within 30 days, 
unstable angina pectoris, percutaneous transluminal angio- 
plasty within 3 months, coronary artery bypass urgery, uncon- 
trolled hypertension, valvular heart disease, dilated cardiomy- 
opathy, history of sustained ventricular tachycardia, baseline 
electrocardiographic (ECG) abnormalities precluding ST seg- 
ment analysis or prior eerebrovascular accident were excluded. 
The study protocol was approved by human research commit- 
tees at the 20 participating centers, and all patients provided 
written informed consent. 
Stress protocols. Before stress testing, beta-blockers were 
withheld for at least 48 h. Symptom-limited arbutamine and 
exercise stress tests were performed. Tests were also termi- 
nated because of maximal heart rate response (->85% of the 
age-predicted maximal heart rate [220 - age], no further heart 
rate increase with continued arbutamine infusion or end of 
exercise protocol), ->2-ram ST segment deviation, clinically 
significant arrhythmia, hypotension (subjectively defined by the 
physician supervising the stress test) or development of intol- 
erable symptoms. Three-lead continuous ECG monitoring was 
performed uring stress and in the recovery period. In addi- 
tion, 12-lead ECGs were recorded every 2 min during arbu- 
tamine infusion and at the end of each exercise stage. To 
ensure consistency in the reporting of arrhythmias, represen- 
tative ECG tracings of all arrhythmias were obtained uring 
arbutamine and exercise stress tests. At -1  rain before the 
termination of arbutamine infusion or exercise, 2.5 to 3.5 mCi 
of thallium-201 was injected intravenously. 
Arbutamine protocol. Arbutamine was administered by a 
unique computer-controlled, heart rate feedback (closed-loop) 
delivery system; that is, the infusion rate was adjusted accord- 
ing to heart rate data feedback. The system was designed to 
infuse arbutamine according to the rate of heart rate increase 
(heart rate slope, range 4 to 12 beats/min per rain) up to the 
maximal heart rate (heart rate target) determined by the 
physician before the test. For the present study, the selected 
heart rate slope was 8 beats/min per min, and the selected 
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heart rate target was 85% of the age-predicted maximal heart 
rate. The delivery system terminated arbutamine infusion if a 
total dose of 10 p.g/kg body weight was administered or if no 
further increase in heart rate at the maximal infusion rate of 
0.8 ~g/kg per min was achieved. Atropine was not adminis- 
tered to supplement heart rate response. The system automat- 
ically monitored heart rate at 5-s and blood pressure at 2-min 
intervals throughout the infusion period. The delivery system 
provided audible and visual messages inresponse to potentially 
significant changes in heart rate or blood pressure and auto- 
matically interrupted arbutamine infusion if the heart rate or 
blood pressure changes exceeded the preprogrammed limits. 
At the end of the test, results were summarized on the device 
printout, and complete data were stored on magnetic media 
using a laptop computer linked to the system. 
Exercbe protocol. The standard Bruce exercise protocol 
was used (17). Heart rate was recorded using a 12-lead ECG, 
and blood pressure was measured using a mercury sphygmo- 
manometer atthe end of each treadmill exercise stage. 
Thallium-201 SPECT imaging. Stress thallium-201 SPECT 
acquisition was initiated within 10 to 15 min after stress and 
redistribution imaging within 3 to 5 h after stress. Thallium-201 
(1.0 to 1.5 mCi) was reinjected before redistribution imaging if 
a fixed defect was anticipated (i.e., prior history of myocardial 
infarction, ischemic linical or ECG response to stress, nonre- 
versible defects on prior thallium-201 studies or thallium-201 
perfusion defects after econstruction f the stress image). The 
SPECT acquisition was performed using a rotating gamma 
camera over a 180 ° arc (30 to 32 images/study, 40 s/image), 
extending from the 45 ° right anterior oblique to the 45 ° left 
posterior oblique projection, with a 20% symmetric energy 
window centered on the 80-keV peak and a 20% symmetric 
window centered on the 167-keV peak of thallium-201. All 
projection images were stored on magnetic media in a 16-bit, 
64 × 64 digital matrix. 
Image analysis. The SPECT images were processed and 
interpreted ata central site. Raw data from the study sites were 
translated into Siemens Microdelta format using a Siemens 
ICON connectivity package. Filtered back projection was 
performed using a Butterworth filter with a cutoff requency of 
0.50% of Nyquist, order of 5, to reconstruct the transaxial slices 
at a thickness of 6.4 mm. The image display and visual 
interpretation method has been previously described (18). 
Briefly, short-axis and vertical ong-axis tomograms were dis- 
played on transparency film and divided into 20 segments for 
semiquantitative visual analysis using a five-point scoring sys- 
tem (0 -- normal; 1 = mild reduction; 2 : moderate r duction; 
3 = severe reduction; 4 = absent radioisotope uptake). The 
images were scored independently b consensus of two expe- 
rienced observers who had no knowledge of the source of the 
tomograms and the results of other study procedures. If a 
consensus was not reached, a third observer esolved the 
discrepancy. A segment with a stress core ->2 was considered 
abnormal with a perfusion defect. A reversible defect was 
defined as an abnormal segment with a redistribution score -< 1 
or -<2 for segments with a stress score of 4. A study was 
considered diagnostic of coronary artery disease if two or more 
segments had a stress core ->2 or at least one segment had a 
stress score ->3; less abnormality was considered negative for 
coronary artery disease. 
Stress ECG. All ECG data were submitted for safety and 
efficacy evaluation to a central laboratory that was independent 
of the scintigraphic and coronary angiography laboratories. An 
ischemic ECG response was defined as ->1 mm horizontal or 
downsioping ST segment depression or ->1 mm ST segment 
elevation in leads without Q waves at 60 ms after the J point. 
Coronary angiography. Coronary angiography was per- 
formed according to routine clinical practice at each investi- 
gational site. Angiograms were interpreted ata central analysis 
site that did not participate in patient recruitment. Angio- 
graphic data were reviewed without knowledge of clinical, 
stress test, ECG or scintigraphic results. Images were produced 
from the original cine films, and the absolute minimal and 
maximal vessel diameters and percent stenosis were calculated 
using Image Comm System (Image Comm, Inc.) quantitative 
coronary angiography analysis oftware (19,20). For the two 
study centers ubmitting angiographic data on videotape, the 
relative percent diameter stenosis was determined using digital 
calipers. Two arbitrary cutoff points were used for definition of 
coronary artery disease: ->50% and ->70% lumen diameter 
narrowing. 
Adverse events. All events, regardless of causal relation to 
the stress test, were collected and recorded. 
Statistical analysis. Changes in hemodynamic variables 
(baseline to peak) were assessed using a paired t test. Hemo- 
dynamic measurements at specific time points and maximal 
and percent changes were compared between arbutamine and 
exercise tests using a repeated measures analysis of variance 
(ANOVA) or a rank-transformed ANOVA for two-period 
crossover data. Estimates and 95% binomial confidence inter- 
vals of sensitivity in the diagnosis of coronary artery disease 
(from SPECT perfusion) and ischemia (from ECG findings) 
were provided for each stress test. Results of the two stress 
tests were compared using the Fisher exact est or a continuity- 
corrected chi-square test for crossover data. Similar point and 
interval estimates of normalcy were also provided. Percent 
agreement in segmental results between the two stress tests 
were summarized, and concordance was examined using the 
kappa coefficient. Other summary statistics included mean 
value _+ SD and number (percent) of patients or segments. All 
statistical tests were performed at the 0.05 significance level, 
except for the test for unequal carryover effects, which was set 
at the 0.10 level (21). 
Results 
Hemodynamic effects. Hemodynamic data were complete 
for analysis in 120 catheterization a d 60 low likelihood group 
patients who received arbutamine. As shown in Table 2, 
statistically significant (p < 0.001) increases in heart rate, 
systolic and diastolic blood pressures and rate-pressure prod- 
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Table 2. Hemodynamic Effects of Arbutamine in the Two 
Study Groups 
Catheterization 
Group 
(n = 120) 
Low Likelihood 
Group 
(n = 60) 
Heart rate (beats/rain) 
Baseline 70 ± ll 68 ± 11 
Maximum 123 ± 12 129 ± 12 
Difference baseline to 53 ± 13 61 ± 11 
maximum 
Systolic BP (mm Hg) 
Baseline 138 - 19 123 + 15 
Maximum 173 ± 23 164 ± 18 
Difference, baseline to 35 ~ 18 41 ± 15 
maximum 
Diastolic BP (ram Hg) 
Baseline 81 : 10 72 ± 13 
Maximum 90 - 11 84 + l 1 
Difference, baseline to 9 : 9 12 ± 10 
maximum 
Minimum 64 ___ 12 51 ± 12 
Difference, baseline to -17 ± 10 -22 _+ 12 
minimum 
Rate-pressure p oduct 
(beats/rain ×mm Hg) 
Baseline 9,948 ± 2,249 8,587 ± 2,120 
Maximum 19,516 _+ 3,453 19,001 _* 2,780 
Data presented are mean value ± SD. BP = blood pressure. 
uct were achieved during arbutamine stress in both study 
groups. 
Of the 69 catheterization group patients who underwent 
both arbutamine and exercise stress testing, hemodynamic data 
were complete for both tests in 63. Baseline and peak heart 
rate and rate pressure product were significantly higher (p < 
0.001) with exercise than arbutamine (Fig. 1). Changes from 
baseline to maximal heart rate were statistically greater with 
exercise, although the magnitude of the difference (5 beats/ 
min) was not considered clinically significant; changes from 
baseline in systolic blood pressure were similar (Table 3). The 
Table 3. Maximal Increase in Hemodynamic Variables From 
Baseline Values for Catheterization Group Patients Who Performed 
Arbutamine and Exercise Stress Tests 
Arbutamine Exercise 
(n - 63) (n = 63) p Value 
Heart rate increase (beats/min)* 53 ± 14 58 -_+ 20 0.035 
Systolic BP increase (mm Hg)* 35 _+ 16 40 - 19 0.073 (NS) 
Diastolic BP increase (ram Hg)* 8 -+ 9 5 -- 7 0.003 
*Increase from baseline tomaximum. Data presented are mean value _± SD. 
BP = blood pressure. 
percent change from the respective baseline values were not 
different for either heart rate (81 _+ 30 vs. 76 _+ 36, p -- 0.283) 
or systolic blood pressure (26 _+ 13 vs. 30 _ 16, p = 0.172) 
between arbutamine and exercise. 
Sensitivity and normalcy rates. The diagnostic efficacy of 
arbutamine thallium-201 SPECT was evaluated in 112 of the 
122 patients with coronary artery disease and 58 of the 62 
patients with a low likelihood of coronary artery disease who 
had complete and interpretable thallium-201 SPECT data. 
Comparisons of arbutamine and exercise were made in the 63 
patients within the catheterization group who underwent both 
forms of stress and had complete SPECT data sets. 
For the criterion of >50% stenosis as significant coronary 
artery disease, the overall sensitivity of arbutamine thallium- 
201 SPECT was 87% (97 of 112 patients). For >70% stenosis 
considered significant, he sensitivity was 95%. The normalcy 
rate in the 58 patients with a low likelihood of coronary artery 
disease was 90% (52 patients). In patients without a prior 
myocardial infarction, the sensitivity of arbutamine thallium- 
201 SPECT was 79% (45 of 57 patients) for ->50% stenosis and 
90% (37 of 41 patients) for ->70% narrowing. 
Comparison of patients who achieved the 85% age- 
predicted maximal heart rate (39 [35%] of 112 in the cathe- 
terization group, 9 [16%] of 58 in the low likelihood group) 
and patients who attained another infusion end point below 
the heart rate target (73 [65%] of 112 in the catheterization, 
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Figure 1. Comparison of hemody- 
namic responses to arbutamine 
(solid columns) versus exercise 
(open columns) in 63 catheteriza- 
tion group patients. Data shown 
are mean value (columns) _+ SD 
(error bars), bpm = beats/min. 
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Arbutamine 
+ 
A~u~mine  
REV Non-REV 
El i"  
+ 330 62 REV 203 25 
ETT 
- 45 823 Non- 
REV 21 81 
Agreement 1153/1260 (92%) 
Kappa = 0.80, p < 0.001 
Agreement 284/330 (86°/.) 
Kappa = 0.68, p < 0.001 
Figm'e 2. The SPECT segmental score agreement forpresence (+) or 
absence (-) of stress defects and defect reversibility. ETI" = exercise; 
REV = reversible defect. 
and 49 [84%] of 58 in the low likelihood group) revealed no 
significant difference in arbutamine thallium-201 SPECT sen- 
sitivity (79% and 90%, p = 0.11) and normalcy rate (89% and 
90%, p = 0.94). 
Subanalysis of sensitivity for detection of coronary artery 
disease according to number of vessels with ->50% diameter 
stenosis showed a trend toward increasing sensitivity with 
increasing numbers of stenosed vessels (78% for single-vessel, 
88% for double-vessel and 92% for triple-vessel disease). 
Using the ->70% diameter stenosis criteria, sensitivity was 
similarly high (94% to 97%) regardless of the number of 
coronary arteries involved. 
In patients who performed both arbutamine and exercise 
stress tests, thallium-201 SPECT sensitivity for detection of 
->50% stenosis was 97% (61 of 63 patients) with exercise and 
94% (59 of 63 patients) with arbutamine (p = NS) and 98% for 
detection of ---70% stenosis with either form of stress. 
Segmental agreement between arbutamine and exercise. 
Of the 1,260 SPECT myocardial segments in63 patients, 1,153 
(92%, kappa 0.80) were concordant and classified as abnormal 
(stress core ->2) or normal by both arbutamine and exercise 
(Fig. 2). In patients without prior infarction, 598 of the 640 
segments were concordant (93%, kappa 0.84). Further analysis 
of discordant segments showed that there were 4% (n = 17) 
fewer stress defects with arbutamine than with exercise (p = 
NS). Among the 330 stress SPECT segments hat were visually 
interpreted as abnormal by both arbutamine and exercise, 
agreement for defect reversibility was 86% (kappa 0.68). There 
was no systematic overestimation r underestimation of defect 
reversibility by either stress method. Exact agreement for stress 
defect scores was 83% (kappa 0.69) (Fig. 3). Analysis of 
discordant segments howed that 24% (104 of 438) of the 
arbutamine thallium-201 SPECT segments with a stress core 
->1 had a lower corresponding score by exercise studies. 
Identically, 24%, (106 of 446) of exercise SPECT segments with 
a stress score ->1 had a lower corresponding score by arbu- 
tamine. 
Electrocardiographic diagnosis of coronary artery disease. 
Electrocardiographic ST segment changes diagnostic of myo- 
cardial ischemia were recorded in 64 of the 122 patients 
receiving arbutamine in the catheterization group, resulting in 
Arbutamine Segment Score 
0 1 2 3 4 
0 752 27 31 4 0 
1 20 24 10 0 0 
Exercise 2 43 12 155 28 0 
Segment 
Score 
3 7 0 23 105 4 
4 0 0 0 1 14 
Exact Agreement 1050/1260 (83%) 
Kappa = 0.69, p < 0.001 
Figure 3. The SPECT myocardial segmental score agreement for 
severity of stress thallium-201 defects. Boldface numbers =segments 
with exact agreement. 
a sensitivity of 52%, whereas detection of 70% stenosis was 
50%. Among the 69 patients in the catheterization group who 
completed both stress tests, ECG sensitivity was similar be- 
tween arbutamine and exercise (47% and 43%, respectively). 
The ECG normalcy rate in the 63 patients with a low likelihood 
of coronary artery disease was 76% (49 patients). 
Adverse vents. Noncardiac adverse vents. Noncardiac ad- 
verse events were observed with similar frequency in patients 
in both the catheterization a d low likelihood groups who 
performed arbutamine t sts. Overall, the most frequent non- 
cardiac events were tremor (23%), flushing (10%), headache 
(10%), paresthesia (8%), dizziness (8%) and hot flushes (4%). 
The majority of adverse vents were mild; the median time for 
resolution after the end of infusion was 6 min. 
Arrhythmias. Arrhythmias were observed in the majority of 
patients during exercise (59% in the catheterization group) or 
arbutamine t sting (75% in the catheterization group and 53% 
in the low likelihood group). Most were premature ventricular 
and atrial contractions. Arrhythmias ofclinical concern for the 
catheterization groups occurred in 10 of 122 (8%) patients 
during arbutamine stress and in 1 (1.4%) of 69 patients during 
exercise, as well as in 2 (3%) of 62 patients during arbutamine 
stress in the low likelihood group (Table 4). No episodes of 
sustained ventricular tachycardia (i.e., ->30 consecutive beats) 
or ventricular fibrillation were observed. The two patients who 
experienced atrial fibrillation were asymptomatic, and the 
arrhythmia resolved spontaneously without intervention. Over- 
all, arrhythmia resulted in discontinuation f arbutamine in
seven of the patients (5%), and one patient received medical 
treatment with intravenous metoprolol for ventricular bigem- 
iny and couplets. 
Hypotension. The frequency of hypotension was similar 
(7% and 8%, respectively) in the catheterization a d low 
likelihood arbutamine groups. Hypotension was transient 
(-<5 min) in all five patients with this event in the low 
likelihood group and in five of eight patients in the catheter- 
ization group. In the other three patients, hypotensive episodes 
lasting 12, 18 and 21 min occurred; infusion was discontinued 
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Table 4. Incidence ofClinically Significant Arrhythmias During Arbutamine and Exercise Stress Tests 
Arbutamine 
Exercise: 
Catheterization Catheterization Low Likelihood 
Group Group Group 
(n 69) (n = 122) (n = 62) 
[no. (%) of pts] [no. (%) of pts] [no. (%) of pts] 
Arrhythmias 1 (1.4) 10 (8) 2 (3) 
PVCs* 0 Ill) 4 (3) 0 (0) 
Supraventricular tachycardia 1 (1.4) 2 (1.6) 0 (0) 
Ventricular tachycardiat I) (I)) 2 (1.6) 0 (0) 
Atrial fibrillation 0 (0) 2 (1.6) 0 (0) 
Junctional rhythm I) (0) 1 (0.8) 1 (1.6) 
Sinoatrial block 0 (0) O (0) 1 (1.6) 
*Includes couplets, bigeminy and multifocal premature ventricular contractions (PVCs). tDefined as three or more 
consecutive ventricular beats at a rate of >100 beats/min, pts = patients. 
in two patients, and one patient experienced dizziness. For the 
entire study cohort (n -- 184), hypotension resulted in the 
discontinuation f arbutamine infusion in 11 patients (5%), 
and treatment (intravenous normal saline solution) was admin- 
istered in 1 patient (0.5%). Exercise hypotension was observed 
in none of the patients. 
Angina. In the catheterization group angina was noted in 
70 patients (57%) during arbutamine and in 30 (44%) during 
exercise stress tests. Anginal pain was considered to be severe 
or prolonged in six catheterization group patients (5%) who 
received arbutamine. Prolonged ST segment depression of 10 
and 13 rain after the end of the infusion was observed in two 
patients (1.3% of the catheterization group), which resolved 
after intravenous metoprotol. Although none of the low like- 
lihood group patients experienced angina, 8% reported non- 
specific hest pain. 
Discuss ion  
The present study describes the first prospective, multi- 
center, controlled clinical evaluation of arbutamine used for 
pharmacologic stress in conjunction with thallium-201 
SPECT imaging. Clinical sites followed the study protocol, 
which standardized stress test conduct, SPECT acquisition 
and thorough collection of safety data. Diagnostic data 
(thallium-201 SPECT scans, angiogram and ECGs) were 
reviewed at independent central aboratories to eliminate 
reviewer bias. 
Arbutamine and its delivery device. Arbutamine is a syn- 
thetic catecholamine that is structurally similar to dobutamine 
and was developed specifically for pharmacologic stress testing. 
In an animal model, Young et al. (11) demonstrated that 
arbutamine has a more potent chronotropic effect han dobut- 
amine for a given increase in contractility. Other studies of 
catecholamines and exercise (12,22-24) suggest that the chro- 
notropic effect may be more important than the inotropic effect 
for induction of ischemia. These results provided the rationale 
for the clinical development of arbutamine. 
To facilitate the ease of infusion and monitoring during stress 
testing, arbutamine is delivered through acompact, computerized 
closed-loop infusion system with ECG and hemodynamic moni- 
tors. The system automatically regulates the arbutamine infusion 
rate according to the patient's heart rate response, discontinues 
the infusion if hemodynamic variables exceed programmed limits 
and provides audible and visual warnings to facilitate monitoring 
of infusion and hemodynamic variables. The device controls the 
infusion at the selected "heart rate slope" to maintain asmooth 
increment of heart rate over time up to the predetermined 
maximal heart rate. The maximal infusion dose and infusion rate 
are also preset o prevent untoward catecholamine overstimula- 
tion. Utilization of the device, therefore, enables accurate and 
safe dose delivery while potentially reducing the labor intensive- 
ness of the stress test. 
Hemodynamie r sponse. Arbutamine resulted in signifi- 
cant increases in heart rate and blood pressure in both low 
likelihood and catheterization group patients. Comparisons of 
the hemodynamic results in catheterization group patients who 
performed both arbutamine and exercise stress tests (n = 63) 
found similar percent increases in heart rates and systolic 
blood pressures from baseline values. However, the peak stress 
heart rate achieved was 16% (p < 0.01) higher with exercise 
than arbutamine stress (Fig. 1). The differences may, in part, 
be explained by differences in the test position of patients 
(supine for arbutamine, upright for treadmill exercise), which 
resulted in different baseline heart rates, as well as the 
definition of the test end points: With arbutamine stress, the 
infusion was discontinued if 85% of the age-predicted maximal 
heart rate was achieved; with exercise, the stress test was 
symptom limited. In fact, 65% of the patients achieved >85% 
of their maximal predicted heart rate with exercise. These 
findings uggest that arbutamine can be used safely to induce 
chronotropic stimulation similar to exercise with similar diag- 
nostic yields. The chronotropic and inotropic actions of arbu- 
tamine may make it a useful stress agent for assessing myocar- 
dial function in conjunction with first-pass (25) or gated 
SPECT imaging (26,27). Furthermore, because the patient is 
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lying still for arbutamine stress, acquisition of first-pass func- 
tion studies in conjunction with myocardial perfusion imaging 
may be facilitated compared with performing nuclear stress 
function studies at peak exercise (25). 
Review of published reports uggests that dobutamine may 
be unable to achieve the heart rate response observed with 
arbutamine. Studies of dobutamine (maximal infusion rate 
40/~g/kg per min) resulted in peak heart rates of 89 to 118 
beats/min (28,29). Only when atropine was included in the 
dobutamine stress protocol (30-32) were heart rates similar to 
those achieved with arbutamine observed (129 to 131 beats/ 
min). The observations derived from the comparisons of these 
clinical studies corroborate previous animal work (11,12) that 
documented arbutamine as having greater chronotropic effects 
than dobutamine at similar levels of inotropic response. Thus, 
although clinical comparisons with dobutamine in the same 
patient cohort may be warranted, the arbutamine infusion 
protocol used in the present study achieved stress heart rates 
comparable to those achieved with exercise without supple- 
mental atropine. 
Published reports further suggest (32) that induction of 
ischemia by dobutamine may be compromised in patients who 
do not reach 85% of the age-predicted maximal heart rate 
target and might require atropine administration to supple- 
ment he heart rate response. In the present study, arbutamine 
thallium-201 SPECT sensitivity and normalcy rate were not 
significantly different in patients who reached the 85% age- 
predicted maximal heart rate and in patients who achieved 
other infusion end points. Therefore, it is unlikely that the use 
of atropine to supplement heart rate during arbutamine stress 
would provide any incremental diagnostic benefit. 
Diagnostic efficacy. Although coronary angiography repre- 
sents an anatomic standard for the determination of coronary 
artery disease, it does not evaluate the functional significance 
of stenosed arteries. Therefore, criteria for defining significant 
coronary artery disease on the basis of percent diameter 
stenosis of major coronary vessels are somewhat arbitrary. In 
the present study, the sensitivity for detecting coronary disease 
was determined using two commonly accepted angiographic 
definitions of coronary disease (->50% or ->70% diameter 
stenosis). 
Sensitivity. Arbutamine thallium-201 SPECT was a highly 
sensitive stress method for detecting coronary artery disease 
(87% and 95% sensitivity for ->50% and ->70% diameter 
stenoses, respectively). These results are similar to previously 
reported figures for stress thallium-201 SPECT, with a mean 
sensitivity of 90% (range 82% to 98%) (1). The results are also 
similar to the reported sensitivity for dobutamine thallium-201 
SPECT, which have ranged from 76% to 97% (28,33,34). 
Importantly, because the majority (88%) of the catheterization 
group patients had completed coronary angiography before 
stress testing, the referral bias whereby patients with positive 
thallium scan responses were preferentially referred for car- 
diac catheterization, which in turn may result in an overesti- 
mation of test sensitivity (14), is unlikely to be operative in this 
cohort (further discussed in next section). 
In the 69 patients who had both arbutamine and exercise 
studies, the sensitivity results were similar for the overall 
detection (->50% stenosis, 94% vs. 97%; ->70% stenosis, 98% 
vs. 98%, respectively). The similarity in scintigraphic efficacy is 
corroborated by the high degree of SPECT segmental gree- 
ment for the presence, xtent and severity of stress myocardial 
perfusion defects as well as for defect reversibility extent (Fig. 
3 and 4). 
Although less sensitive than thallium-201 SPECT, the ECG 
sensitivity for arbutamine was also comparable to that for 
exercise. In published studies comparing dobutamine and 
exercise (35,36), the ECG sensitivity was consistently lower 
with dobutamine than with exercise (i.e., 11% vs. 35% and 
32% vs. 77%, respectively). Other studies (28,29,32,37) have 
shown the ECG sensitivity of dobutamine (with or without 
atropine) to be in the range 19% to 28%. The comparable 
sensitivity to exercise stress in the present study may suggest a
potential clinical use of arbutamine for the ECG evaluation of 
coronary artery disease among patients who cannot exercise. 
Normalcy rates as a proxy of test specificity. Because of the 
recognition and reliance on the accuracy of stress myocardial 
scintigraphic studies, there has been an increasing prevalence 
of referral bias whereby patients with positive thallium-201 test 
results are preferentially referred for coronary angiography. 
Selection of these patients for angiography has led to a major 
underestimation f scintigraphic test specificity and, to a lesser 
degree, to an overestimation of test sensitivity (13,14,38). 
Because it is unlikely that a random sample of patients with 
suspected coronary artery disease will undergo catheterization 
regardless of thallium-201 results, the true specificity of the 
thallinm-201 SPECT study will be difficult to determine. 
Therefore, as a proxy for specificity, it has been previously 
suggested (13,14,38) that normalcy rate is a more suitable 
assessment of the myocardial scintigraphic test than conven- 
tional specificity derived from patients with normal coronary 
arteriographic results. Additionally, because the normalcy rate 
is evaluated in patients with a low pretest likelihood of 
coronary disease who are clinically referred for stress testing 
and are closer in age and symptoms to patients with coronary 
artery disease, normalcy rate is a better estimate of specificity 
than evaluation of typically healthy normal volunteers. The 
normalcy rate for arbutamine thallium-201 SPECT was 90%, 
which is comparable to published exercise thallium-201 
SPECT results (2,14,39). These findings suggest that the 
observed normalcy rate from the present study may indeed be 
close to the true specificity for arbutamine thallium-201 
SPECT used for the diagnosis of coronary artery disease. 
Incidence of symptoms and adverse events. To ensure 
consistent reporting methods at each center, all events, regard- 
less of relation to the stress test, were collected and evaluated. 
As expected with the administration of a beta-agonist, more 
patients experienced adverse events temporally related to 
arbutamine than to exercise. In general, events were mild and 
resolved with discontinuation of the infusion. 
Arrhythmias. Arrhythmias were the most frequent cardiac 
adverse vents for arbutamine stress, with clinically significant 
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arrhythmias occurring in 3% of low likelihood and 8% of 
catheterization group patients receiving arbutamine versus 
1.4% of patients who performed exercise. Importantly, there 
were no differences in the low frequency of nonsustained 
ventricular tachycardia, supraventricular tachycardia or atrial 
fibrillation for the two stress methods, with premature ventric- 
ular or atrial beats representing the predominant form of 
arrhythmia occurring during either stress method. Patients 
with a low likelihood of coronary artery disease had a slightly 
lower incidence of arrhythmias, most likely reflecting the 
expected increase in propensity for both atrial and ventricular 
ectopic activity among patients with coronary artery disease. 
The reported (33,34,40) overall incidence of arrhythmias with 
dobutamine ranges from 35% to 53%, which is similar to the 
findings of the present study. 
Chest pain. Chest pain frequently occurred with arbu- 
tamine or exercise in catheterization group patients (57% vs. 
44%, respectively), suggesting that, in contrast to vasodilator 
stress, where chest pain is a nonspecific symptom (41,42), chest 
pain is likely to be a more specific symptom for the presence of 
ischemia. This contention is supported by the observation that 
ischemic hest pain did not occur and nonischemic chest pain 
rarely (8%) occurred among the low likelihood group during 
arbutamine stress. 
Hypotension. In our study, the infusion device contributed 
to standardization f the definition of hypotension because all 
changes in blood pressure that exceeded preprogrammed 
limits were identified. Clinicians then applied clinical judgment 
to determine whether the blood pressure change constituted 
an adverse event; in any case, any blood pressure decrease 
associated with symptoms was recorded as an adverse vent. A 
hypotensive r sponse occurred in 8% of patients during arbu- 
tamine but was not observed with exercise. The incidence was 
similar in the catheterization a d low likelihood groups and, 
therefore, is not considered to be related to the presence or 
extent of coronary artery disease. Hypotension is also observed 
with dobutamine and is thought o be mediated by either 
beta2-adrenoceptor vasodilation or by beta I stimulation caus- 
ing a reflex decrease inblood pressure (43). Vasovagai reflexes 
in response to dobutamine are often accompanied by brady- 
cardia (44); however, hypotension associated with bradycardia 
was seen in only two patients. 
Noncardiovascular events. The most frequently reported 
noncardiovascular events after arbutamine were similar to 
those reported for dobutamine and were consistent with the 
pharmacologic mechanism of beta-agonist stimulation. The 
events generally resolved with the termination of infusion, 
consistent with the relatively short pharmacokinetic half-life of 
arbutamine (8 min). However, if it is considered clinically 
necessary, the beta-adrenergic activity of arbutamine may be 
attenuated byadministration f a rapid-onset yet short-acting 
beta-blocker, such as intravenous e molol. 
Study limitations. Clinical comparisons of the hemody- 
namic responses to arbutamine and exercise are limited by the 
dissimilar heart rate end points for the two tests. The arbu- 
tamine stress protocol imited the maximal achievable heart 
rate to 85% of the patient's age-predicted maximal heart rate. 
However, the treadmill protocol allowed patients to continue 
beyond this heart rate limit if other end points had not been 
achieved. Nevertheless, the arbutamine thallium-201 SPECT 
results demonstrated similar sensitivity and a high degree of 
myocardial segmental score agreement with exercise studies, 
without evidence of underestimation of the presence, xtent or 
severity of myocardial perfusion defect. These concordances 
most likely reflect he presence of a similar degree of ischemia 
by arbutamine stress compared with exercise. However, be- 
cause of the inclusion of patients with prior myocardial infarc- 
tion, the reported overall sensitivities for both exercise and 
arbutamine stress tests may be overestimated. 
Conclusions. Arbutamine, administered by a closed-loop 
delivery device and used in conjunction with thallium-201 
SPECT, was shown in a multicenter trial to be effective for the 
detection of coronary artery disease in patients with angio- 
graphic evidence or those with a low pretest likelihood of 
coronary artery disease. Comparable sensitivity of arbutamine 
and exercise stress testing was demonstrated forboth thallium- 
201 SPECT and ECG detection of coronary artery disease. In 
patients with coronary artery disease, as well as those with a 
low pretest likelihood of coronary disease, arbutamine was well 
tolerated with an acceptable safety profile. 
We thank Cindy Williams, CNMT, Debra Liebert, MS and Anthony Andrasfay, 
BS for their report and technical assistance. 
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